Biovail shareholders vote proxies today; Lupin: FDA warning won't hit bottom line;

> Biovail's proxy vote happens today; the company made a last-ditch pitch to shareholders to vote for its slate of directors rather than founder Eugene Melnyk's nominees. Release

> Indian generics maker Lupin doesn't expect its finances to be affected by a recent the FDA warning against one of its manufacturing units. Report

> SkyePharma moved a step closer to getting its new asthma drug Flutiform approved in the U.S. after the FDA accepted the medicine for review. Report

> Johnson & Johnson agreed to acquire cancer drug developer Cougar Biotechnology for about $970 million in cash in order to strengthen its oncology business. Report

> Doctors who gave diabetics a generic drug originally intended to lower patients' cholesterol found it reduced their risk of so-called minor amputation by 36 percent. Report

> A bill giving the FDA power to regulate tobacco products won approval from a key US Senate panel Wednesday, clearing the way for a full Senate vote. Report

> Dr. Mark Geier describes himself as the scientist who has solved the mystery of autism, fingering thimerosal in vaccines for the devastating disease. Report

> The swine flu outbreak has focused a spotlight on new research underway for a universal flu vaccine. Report

> GlaxoSmithKline has already received orders for 128 million doses of a new swine flu vaccine that has yet to be developed. And the pharma giant says that it expects many, many more requests before it's all over. Report

> A group of Swedish researchers say that they have developed a new HIV vaccine that can be produced in plants and has proven effective in mice. Report

> The NIH has long been the godfather of preclinical research work that later went on to form the foundation IP for emerging biotech companies. Now the newly flush agency plans to start funding preclinical programs designed specifically to hand off to developers. Report

> The management team that built up Pharmion and sold it to Celgene last year for $2.9 billion have regrouped, lined up $145 million in funding and launched a new biotech company that will follow their old business plan. Report

> The FDA is facing a pair of big PDUFA dates, and the agency's conclusions will make or break two would-be blockbusters--Xarelto and GSK and Genmab's Arzerra. Report

> Novartis announced positive results after testing its respiratory drug QAB149 in a late-stage, head-to-head study with two established therapeutics. All doses of the drug met the primary endpoint in the COPD study, and the pharma giant believes it has a potential blockbuster therapy on its hands. Report

> A pair of U.S. biotech companies has collectively raised more than $64 million in increasingly scarce venture funds. Report

And Finally... The promise of internet marketing: An online video series created by Johnson & Johnson for its Clean & Clear brand has had more than 218,000 views. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.